Adzynma is a purified recombinant form of the ADAMTS13 protein designed to replace the missing or deficient ADAMTS13 enzyme. The Food and Drug Administration (FDA) has approved Adzynma for ...
The COVID-19 pandemic has prompted the rapid development and administration of various vaccines worldwide, with some reports linking these vaccines to immune thrombotic thrombocytopenic purpura (TTP).
The COVID-19 pandemic has prompted the rapid development and administration of various vaccines worldwide, with some reports linking these vaccines to immune thrombotic thrombocytopenic purpura (TTP).
Researchers from the Second Affiliated Hospital of Nanjing Medical University, et al. have published a case report entitled "Acquired immune thrombotic thrombocytopenic purpura (TTP) associated with ...
The patient’s thrombotic thrombocytopenic purpura (TTP)–like symptoms were caused by deficiencies of vitamins B1 and B12. Patients with apparent symptoms of thrombotic thrombocytopenic purpura (TTP) ...
The researchers noted that their paper is the first, to their knowledge, to report on a case of thrombocytopenic purpura (TTP) in a patient with metastatic renal cell carcinoma (RCC). Authors of a new ...
− cTTP is an Ultra-rare, Potentially Fatal Blood-Clotting Disorder with Limited Treatment Options; Untreated, Acute TTP Events Have a Mortality Rate of >90%1,2 − Approval Based on Totality of Evidence ...
Congenital thrombotic thrombocytopenic purpura results from severe hereditary deficiency of ADAMTS13. Prophylactic approaches with an improved safety profile are needed. New research findings are ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results